Multiple‐Targeting and Conformational Selection in the Estrogen Receptor: Computation and Experiment

Conformational selection is a primary mechanism in biomolecular recognition. The conformational ensemble may determine the ability of a drug to compete with a native ligand for a receptor target. Traditional docking procedures which use one or few protein structures are limited and may not be able to represent a complex competition among closely related protein receptors in agonist and antagonist ensembles. Here, we test a protocol aimed at selecting a drug candidate based on its ability to synergistically bind to distinct conformational states. We demonstrate, for the case of estrogen receptor α (ERα) and estrogen receptor β (ERβ), that the functional outcome of ligand binding can be inferred from its ability to simultaneously bind both ERα and ERβ in agonist and antagonist conformations as calculated docking scores. Combining a conformational selection method with an experimental reporter gene system in yeast, we propose that several phytoestrogens can be novel estrogen receptor β selective agonists. Our work proposes a computational protocol to select estrogen receptor subtype selective agonists. Compared with other models, present method gives the best prediction in ligands’ function.

[1]  Ruben Abagyan,et al.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles , 2010, J. Comput. Aided Mol. Des..

[2]  S. Ozkan,et al.  A flexible docking scheme to explore the binding selectivity of PDZ domains , 2010, Protein science : a publication of the Protein Society.

[3]  Martin Zacharias,et al.  Accounting for conformational changes during protein-protein docking. , 2010, Current opinion in structural biology.

[4]  Amy C. Anderson,et al.  Scoring Ensembles of Docked Protein: Ligand Interactions for Virtual Lead Optimization , 2009, J. Chem. Inf. Model..

[5]  S. Salvadori,et al.  Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. , 2009, British journal of anaesthesia.

[6]  T. Rajah,et al.  Genistein in the Presence of 17β-Estradiol Inhibits Proliferation of ERβ Breast Cancer Cells , 2009, Pharmacology.

[7]  Ruth Nussinov,et al.  Amplification of signaling via cellular allosteric relay and protein disorder , 2009, Proceedings of the National Academy of Sciences.

[8]  Ajay N. Jain Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation , 2009, J. Comput. Aided Mol. Des..

[9]  Chung F. Wong,et al.  Conformational selection of protein kinase A revealed by flexible‐ligand flexible‐protein docking , 2009, J. Comput. Chem..

[10]  Yan Zhu,et al.  The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  M. Takiguchi,et al.  Insight into estrogenicity of phytoestrogens using in silico simulation. , 2009, Biochemical and biophysical research communications.

[12]  Jian Huang,et al.  A Bipartite Recombinant Yeast System for the Identification of Subtype-Selective Estrogen Receptor Ligands , 2009, Molecular biotechnology.

[13]  H. Wolfson,et al.  Principles of flexible protein–protein docking , 2008, Proteins.

[14]  Adriano D. Andricopulo,et al.  Structure-Based Approach for the Study of Estrogen Receptor Binding Affinity and Subtype Selectivity , 2008, J. Chem. Inf. Model..

[15]  D. Dixon,et al.  A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. , 2008, Human reproduction.

[16]  L. Cubano,et al.  Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. , 2008, Translational oncology.

[17]  Ram Samudrala,et al.  Novel paradigms for drug discovery: computational multitarget screening. , 2008, Trends in pharmacological sciences.

[18]  T. Hei,et al.  Phytoestrogens and Breast Cancer Prevention: Possible Mechanisms of Action , 2008, Environmental health perspectives.

[19]  Andrzej Joachimiak,et al.  Structural plasticity in the oestrogen receptor ligand‐binding domain , 2007, EMBO reports.

[20]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[21]  Takeshi Usui,et al.  Pharmaceutical prospects of phytoestrogens. , 2006, Endocrine journal.

[22]  N. Shah,et al.  Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis , 2005, Menopause.

[23]  F. Stossi,et al.  Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure. , 2005, Journal of medicinal chemistry.

[24]  D. Heber,et al.  Phytoestrogens Induce Differential Estrogen Receptor Alpha- or Beta-Mediated Responses in Transfected Breast Cancer Cells , 2005, Experimental biology and medicine.

[25]  M. Malamas,et al.  Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. , 2005, Bioorganic & medicinal chemistry letters.

[26]  J. Keith,et al.  ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. , 2005, Journal of medicinal chemistry.

[27]  A. Scorilas,et al.  Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction , 2005, Biological chemistry.

[28]  Fabio Stossi,et al.  Indazole estrogens: highly selective ligands for the estrogen receptor beta. , 2005, Journal of medicinal chemistry.

[29]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[30]  Eric S Manas,et al.  Structure-based design of estrogen receptor-beta selective ligands. , 2004, Journal of the American Chemical Society.

[31]  David H. Kaufman,et al.  7-Substituted 2-phenyl-benzofurans as ERβ selective ligands , 2004 .

[32]  Iwan Gunawan,et al.  Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. , 2004, Journal of medicinal chemistry.

[33]  Fabio Stossi,et al.  Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. , 2004, Endocrinology.

[34]  S. O. Mueller,et al.  Phytoestrogens and Their Human Metabolites Show Distinct Agonistic and Antagonistic Properties on Estrogen Receptor α (ERα)and ERβ in Human Cells , 2004 .

[35]  Eric S Manas,et al.  ERbeta ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. , 2004, Bioorganic & medicinal chemistry.

[36]  Y. Liang,et al.  Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats , 2004, Neuroscience Letters.

[37]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[38]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[39]  John A. Katzenellenbogen,et al.  Allosteric Control of Ligand Selectivity between Estrogen Receptors α and β - Implications for Other Nuclear Receptors , 2004 .

[40]  Ajay N. Jain,et al.  Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.

[41]  Nico P E Vermeulen,et al.  Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. , 2004, Journal of medicinal chemistry.

[42]  Vincent W DeLaGarza,et al.  Genetic Predisposition and Environmental Pharmacologic Treatment of Alzheimer's Disease: an Update Clinical Pharmacology , 2022 .

[43]  B. Katzenellenbogen,et al.  Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression , 2003, Molecular and Cellular Endocrinology.

[44]  Eric S Manas,et al.  ERβ Ligands. Part 1: The discovery of ERβ selective ligands which embrace the 4-hydroxy-biphenyl template , 2003 .

[45]  S. Apers,et al.  Phytoestrogens: Recent Developments , 2003, Planta medica.

[46]  Peter Wolohan,et al.  CoMFA and docking study of novel estrogen receptor subtype selective ligands , 2003, J. Comput. Aided Mol. Des..

[47]  Y. Lavy,et al.  [Review of risk factors for breast cancer--what's new?]. , 2002, Harefuah.

[48]  T. Matsumiya,et al.  Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; comparison to the effects of estradiol. , 2002, Biological & pharmaceutical bulletin.

[49]  Tomomi Sato,et al.  The phytoestrogen genistein induces thymic and immune changes: A human health concern? , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  David A. Agard,et al.  Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.

[51]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[52]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[53]  N. Cutler,et al.  Review of the acetylcholinesterase inhibitor galanthamine , 2000, Expert opinion on investigational drugs.

[54]  J. Gustafsson,et al.  Estrogen receptor beta--a new dimension in estrogen mechanism of action. , 1999, The Journal of endocrinology.

[55]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[56]  M. Parker,et al.  Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.

[57]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[58]  J. Gustafsson,et al.  The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems , 1998, Frontiers in Neuroendocrinology.

[59]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[60]  J. Lehmann,et al.  Cloning and Characterization of Human Estrogen Receptor β Isoforms , 1998 .

[61]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[62]  J. Gustafsson,et al.  Characterization of bacterially expressed rat estrogen receptor β ligand binding domain by mass spectrometry: Structural comparison with estrogen receptor α , 1997, Steroids.

[63]  K. Setchell,et al.  Exposure of infants to phyto-oestrogens from soy-based infant formula , 1997, The Lancet.

[64]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[65]  D Rodbard,et al.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.

[66]  T. Kenakin,et al.  Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. , 1989, Molecular pharmacology.

[67]  Joseph P. Salisbury,et al.  Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. , 2009 .

[68]  R. Limberger,et al.  Screening for in vivo (anti)estrogenic activity of ephedrine and p-synephrine and their natural sources Ephedra sinica Stapf. (Ephedraceae) and Citrus aurantium L. (Rutaceae) in rats , 2008, Archives of Toxicology.

[69]  K. Kang,et al.  Estrogenic activities of isoflavones and flavones and their structure-activity relationships. , 2008, Planta medica.

[70]  H. Harris Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential. , 2006, Ernst Schering Foundation symposium proceedings.

[71]  R. Henderson,et al.  7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. , 2004, Bioorganic & medicinal chemistry letters.

[72]  B. Katzenellenbogen,et al.  Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. , 2004, Molecular cell.

[73]  S. O. Mueller,et al.  Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[74]  H. Harris,et al.  ERbeta ligands. Part 1: the discovery of ERbeta selective ligands which embrace the 4-hydroxy-biphenyl template. , 2003, Bioorganic & medicinal chemistry.

[75]  J. Lehmann,et al.  Cloning and characterization of human estrogen receptor beta isoforms. , 1998, Biochemical and biophysical research communications.

[76]  J. Gustafsson,et al.  Characterization of bacterially expressed rat estrogen receptor beta ligand binding domain by mass spectrometry: structural comparison with estrogen receptor alpha. , 1997, Steroids.